13Mar

Cardiff University and Cytox to present further results on the implementation of SNPfitR analytical platform in identifying individuals for Alzheimer’s clinical trials at AD/PD conference in Lisbon

cytox-logo

13th March 2019: Oxford & Manchester, UK. Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s (AD) and other neurological diseases, has announced that in collaboration with Cardiff University it will be making a poster and short oral presentation at the multidisciplinary 14th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2019), March 26-31 in Lisbon, Portugal. The presentation will share results on the high accuracy of Cytox’s pioneering SNPfitRTM, an analytical software platform that contains multiple PRS algorithms, in predicting clinical Alzheimer’s disease in both carriers and non-carriers of ApoE4 risk allele, with validation and optimization in independent, well-characterized cohorts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI). In addition, the prediction accuracy in carriers was significantly increased compared with the accuracy achieved using ApoE (E4/E2), age and gender.

Poster 249 titled, ‘The Utility of Polygenic Risk Scores to Identify Individuals for Clinical Trials in Alzheimer’s Disease’, will be displayed all day on Wednesday March 27th, as part of the ‘Imaging, Biomarkers, Diagnostics: Other’ session in the Exhibition Hall at the Lisbon Congress Centre and an oral presentation will be given by Eftychia Bellou, Cardiff University, Cardiff, United Kingdom, in the Short Oral Session 02 – Presentations of Selected Posters on Thursday March 28th, 09:15 - 11:15, Auditorium V.

Richard Pither, CEO of Cytox, commented “The importance of Cytox’s PRS approach is gaining increasing attention for estimating individual genetic risk profile and disease risk prediction in Alzheimer’s – essential in the selection of individuals for clinical trials and cohort studies. Recent results from an international collaborative study have validated this, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals. The results we are presenting at AD/PD further show that SNPfitR provides a valuable platform for determining genetic risk in dementia in both carriers and non-carriers of ApoE4, with the advantage of requiring only blood or saliva-extracted DNA, thus reducing reliance on expensive PET imaging procedures.”

Related

PrimeStore® MTM novel viral transport media successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing cap...

Read More >

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results

Read More >

European Reference Laboratory for Glycohemoglobin study reaffirms EKF’s Quo-Test® meets HbA1c performance criteria

Cardiff, UK – 16th February 2017 – EKF Diagnostics, the global in vitro diagnostics company, annou...

Read More >

Protect Your Samples from Acidification When Shipped On Dry Ice

The new ProtectR® tubes, now available from Alpha Laboratories, have the only container closure syst...

Read More >

SpeeDx and Diagen sign new distribution agreement for Scandinavia

SYDNEY, AUSTRALIA – (Sept 19, 2017). SpeeDx Pty, Ltd. has announced a distribution agreement with D...

Read More >

Isohelix Double Registers its DNA Saliva and Buccal Cell Collectors with the Chinese CFDA.

Isohelix announces that their range of GenefiX DNA Saliva and Isohelix DNA Buccal Cell Collectors ar...

Read More >